Interleukin-2 variants with modified biological activity
AssigneesInstitut Curie, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, Centre National De La Recherche Scientifique
InventorsEliane Piaggio, Sebastian Amigorena, Pamela Caudana, Felix Rey, Gleyder Roman-Sosa, Pablo Guardado-Calvo
Life of this patent
Estimating the term…
Abstract
The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.
Claims14
A human interleukin-2 variant for the prevention or treatment of immune disorders, which is selected from the group consisting of:
- a variant comprising the substitutions K9E, L12E, H16R, L19R, M23L, N26K, S87N, V91K, E95K, N119K, T123A, and S127K;
- a variant comprising the substitutions K9E, L12E, H16R, L19R, M23L, N26K, S87N, V91K, E95K, Y31P, K49Q, E52S, R81E, D84N, N119K, T123A, T131R and L132S;
- a variant comprising the substitution Y31P, wherein the variant does not comprise any substitution at positions 9, 12, 16, 19, 23, 26, 49, 52, 81, 84, 87, 91, 95, 119, 123, 127, 131 and 132;
- a variant comprising the substitutions K9E, L12E, H16R, L19R, M23L, N26K, S87N, V91K, E95K, Y31P, K49Q, E52S, R81E, D84N, T131R and L132S;
- a variant comprising the substitutions K9E, L12E, H16R, L19R, M23L, N26K, S87N, V91K, E95K, Y31P, N119K, T123A, and S127K;
- and
- a variant comprising the substitutions K9E, L12E, H16R, L19R, M23L, N26K, S87N, V91K, E95K, K49Q, E52S, R81E, D84N, N119K, T123A, T131R and L132S;
- wherein the indicated positions are determined by alignment with SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.